Compare PayPal Holdings, Inc. (PYPL) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PayPal Holdings, Inc. vs BIO-TECHNE Corp — how do they compare? PayPal Holdings, Inc. trades at $52.2 (market cap $45.49B), while BIO-TECHNE Corp trades at $72.39 (market cap $11.34B). The key difference: PayPal Holdings, Inc. is far larger — about 4× BIO-TECHNE Corp's market cap, and PayPal Holdings, Inc. pays the higher dividend (1.05%). Which is the better fit depends on your goals.
| PYPL | TECH | |
|---|---|---|
Market Cap | $45.49B | $11.34B |
Sector | Financials | Health |
52-Week High | $76.13 | $72.48 |
52-Week Low | $39.08 | $43.31 |
Enterprise Value | $47.64B | $11.36B |
Dividend Yield | 1.05% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PayPal (PYPL) trades at $53.18, down 3.24% on the day, with a bearish technical outlook but strong fundamentals including a P/E of 10.05 and net income margin of 14.36%. Recent earnings beat expectations in Q1 and Q2 2026, while the company pursues a $1.5B cost-saving initiative and expands beyond branded checkout. Analyst consensus is a $59.61 price target with a mixed rating distribution.
The stock presents a value opportunity given low valuation multiples and solid profitability, but faces headwinds from competitive pressures and recent takeover speculation collapse. Upside depends on successful execution of restructuring and new growth initiatives, while downside risks include market sentiment shifts and execution missteps.
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PayPal Holdings, Inc.
PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.
Read more on PYPL →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
